Indian markets see a mix of news as Adani Power completes a major 10-subsidiary merger and NTPC Green expands solar capacity. Meanwhile, L&T wins a large manufacturing contract, while regulatory updates for Som Distilleries, Fortis Healthcare, and pharma companies like Unichem and Zydus draw investor attention.
Monday’s market session brings significant corporate updates across the power, infrastructure, and pharmaceutical sectors. In the power sector, Adani Power has concluded the merger of 10 wholly owned subsidiaries into the parent company. Following approval from the National Company Law Tribunal, this restructuring aims to simplify the company’s corporate structure and reduce the time and money spent on regulatory compliance. In the renewable space, NTPC Green Energy has increased its solar footprint by commissioning the first 81.34 MW phase of its Bikaner solar project. This addition takes the company’s total operational capacity to over 11,058 MW, a key metric for investors tracking the firm’s renewable energy growth strategy.
Infrastructure and manufacturing companies have also reported fresh business wins. RailTel Corporation of India has secured a contract worth ₹21.57 crore from the Central Mine Planning & Design Institute. In a larger deal for the industrial sector, Larsen & Toubro (L&T) has won a ₹797 crore contract from Rashtriya Chemicals and Fertilizers. This project involves a major upgrade of the ammonia plant at the company’s Thal facility, adding to L&T's order book. Additionally, Chemplast Sanmar has resumed operations at its Karaikal plant. The restart follows the lifting of previous regulatory prohibitions, which is expected to restore the company's production capacity for ethylene dichloride (EDC).
Regulatory and legal developments have created significant movement for several companies. Som Distilleries & Breweries received a positive outcome from the Madhya Pradesh High Court, which quashed a previous order that had denied the renewal of its excise licenses. The court has directed authorities to process these renewals within 15 days, providing relief after the stock faced pressure due to the earlier uncertainty.
In the healthcare sector, Fortis Healthcare remains in focus as the Supreme Court has permitted a forensic audit into past share transfers involving promoters. This follows a long-standing legal saga that continues to be a point of interest for market observers regarding governance. Meanwhile, in the pharmaceutical space, inspection outcomes have varied. Unichem Laboratories faced a USFDA inspection at its Goa site, which resulted in five procedural observations. Investors usually monitor how quickly companies resolve these findings to avoid export hurdles. Conversely, Zydus Lifesciences reported a successful outcome from a USFDA audit of its pharmacovigilance systems in New Jersey, which concluded with no observations, signaling strong compliance standards. Investors may now track how these companies manage their respective regulatory and operational commitments in the coming quarters.